Homocysteine: Is it a clinically important cardiovascular risk factor?

被引：77

作者：

Lentz, SR

Haynes, WG

机构：

[1] Univ Iowa, Dept Internal Med, Gen Clin Res Ctr, Iowa City, IA 52242 USA

[2] Vet Affairs Med Ctr, Iowa City, IA 52242 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2004年 / 71卷 / 09期

关键词：

D O I：

10.3949/ccjm.71.9.729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Elevated plasma homocysteine is associated with an increased risk of myocardial infarction, stroke, and venous thromboembolism. Folic acid and other B vitamins lower plasma homocysteine levels, but whether this therapy confers a clinical benefit has yet to be determined. Until we know the results of ongoing clinical trials of homocysteine-lowering therapy, testing for and treating elevated homocysteine is probably justified only in patients with known cardiovascular disease or who are at high risk.

引用

页码：729 / 734

页数：6

共 45 条

[1] Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease [J].

Austin, RC ;

Lentz, SR ;

Werstuck, GH .

CELL DEATH AND DIFFERENTIATION, 2004, 11 (Suppl 1) :S56-S64

[2] Power shortage: Clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour [J].

Bostom, AG ;

Selhub, J ;

Jacques, PF ;

Rosenberg, IH .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) :133-139

[3] A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].

BOUSHEY, CJ ;

BERESFORD, SAA ;

OMENN, GS ;

MOTULSKY, AG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057

[4]

Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894

[5]

Clarke R, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P477

[6] Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].

Clarke, R ;

Collins, R ;

Lewington, S ;

Donald, A ;

Alfthan, G ;

Tuomilehto, J ;

Arnesen, E ;

Bonaa, K ;

Blacher, J ;

Boers, GHJ ;

Bostom, A ;

Bots, ML ;

Grobee, DE ;

Brattström, L ;

Breteler, MMB ;

Hofman, A ;

Chambers, JC ;

Kooner, JS ;

Coull, BM ;

Evans, RW ;

Kuller, LH ;

Evers, S ;

Folsom, AR ;

Freyburger, G ;

Parrot, F ;

Genst, J ;

Dalery, K ;

Graham, IM ;

Daly, L ;

Hoogeveen, EK ;

Kostense, PJ ;

Stehouwer, CDA ;

Hopknis, PN ;

Jacques, P ;

Selhub, J ;

Luft, FC ;

Jungers, P ;

Lindgren, A ;

Lolin, YI ;

Loehrer, F ;

Fowler, B ;

Mansoor, MA ;

Malinow, MR ;

Ducimetiere, P ;

Nygard, O ;

Refsum, H ;

Vollset, SE ;

Ueland, PM ;

Omenn, GS ;

Beresford, SAA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022

[7]

den Heijer M, 2001, CLIN CHEM LAB MED, V39, P710

[8]

DENHEIJER M, 2003, J THROMB HAEMOST S1, V1, P161

[9] Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence [J].

Eikelboom, JW ;

Lonn, E ;

Genest, J ;

Hankey, G ;

Yusuf, S .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (05) :363-375

[10] Hyperhomocysteinemia - A million ways to lose control [J].

Faraci, FM .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (03) :371-373

← 1 2 3 4 5 →